Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 3SBio, Isotechnika To Develop Voclosporin in China | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

3SBio, Isotechnika To Develop Voclosporin in China

3SBio, Inc. and Isotechnika Pharma, Inc. have signed a development and commercialization agreement for voclosporin, a next-gen calcineurin inhibitor being developed for the prevention of organ rejection and the treatment of autoimmune diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

3SBio, Inc. and Isotechnika Pharma, Inc. have signed a development and commercialization agreement for voclosporin, a next-gen calcineurin inhibitor being developed for the prevention of organ rejection and the treatment of autoimmune diseases.

Isotechnika will grant 3SBio exclusive rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong and Taiwan, and will receive an upfront licensing payment of $1.5 million. 3SBio will be responsible for the clinical development, registration and commercialization of the drug in China. Isotechnika will provide, under separate agreement, commercial supply to 3SBio on a cost-plus basis. Isotechnika will also receive royalties on sales.

“This agreement represents an important milestone for the continued development of voclosporin in transplantation indication worldwide after Isotechnika regained global rights of this product in 2008,” commented Dr. Robert Foster, president and chief executive officer of Isotechnika. “3SBio’s commercial expertise and leading franchise in nephrology in China make the company an ideal partner for the region and provides further validation of voclosporin’s market potential. We continue to seek strategic partnerships in other regions.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics